Want to see HK:2359 full AI Analyst Report?
2359 Stock Chart & Stats
HK$122.90
HK$1.65(3.23%)
At close: 4:00 PM EST
HK$122.90
HK$1.65(3.23%)
Day’s Range― - ―
52-Week RangeHK$90.25 - HK$167.60
Previous CloseN/A
Volume2.88M
Average Volume (3M)6.08M
Market Cap
HK$405.95B
Enterprise ValueHK$269.81K
Total Cash (Recent Filing)HK$43.38B
Total Debt (Recent Filing)HK$8.21B
Price to Earnings (P/E)16.6
Beta1.49
Next Earnings
Aug 03, 2026EPS Estimate
1.82Next Dividend Ex-DateN/A
Dividend Yield1.43%
Share Statistics
EPS (TTM)7.03
Shares Outstanding510,476,900
10 Day Avg. Volume5,559,442
30 Day Avg. Volume6,076,831
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.18
Price to Sales (P/S)5.57
P/FCF Ratio21.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$168.20Price Target Upside36.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)7.01
Revenue Forecast (FY)HK$61.43B
Bulls Say, Bears Say
Bulls Say
High Margins And ReturnsExceptionally high TTM net margin (~42%) and ROE (~27%) indicate durable pricing power and operational efficiency in CRDMO services. Structural margin improvement versus 2022–2024 supports reinvestment capacity and long-term shareholder returns even with variable top-line growth.
Integrated End-to-end CRDMO PlatformA full-service platform across discovery, preclinical, development and manufacturing drives strong customer stickiness and cross‑sell potential. This reduces customer acquisition risk, diversifies revenue sources across project stages and supports long-term contract continuity.
Conservative Balance Sheet / Low LeverageVery low leverage (debt/equity ~0.10) and a larger equity base provide financial flexibility to fund capacity, absorb project timing swings, and pursue strategic investments without pressuring cash flows or requiring immediate capital raises.
Bears Say
Volatile Cash Conversion And FCF DeclineA sharp ~51% TTM free cash flow decline and historically inconsistent cash conversion reduce the reliability of cash available for capex, dividends or debt reduction. For a service firm with project timing variability, this undermines long‑term planning and capital allocation.
Uneven And Modest Revenue GrowthTop-line growth remains modest and uneven despite margin gains. For a capacity‑dependent CRDMO, sustained revenue expansion is needed to drive utilization and scale margins; inconsistent organic growth limits long-term scalability and raises reliance on cyclical project flows.
Rising Absolute Debt LevelsAlthough leverage ratios are low, rising absolute debt versus 2024 increases nominal interest and refinancing exposure. If earnings or cash conversion weaken again, higher absolute debt could constrain flexibility and raise funding costs for future capacity or strategic moves.
WuXi AppTec Co., Ltd. Class H News
2359 FAQ
What was WuXi AppTec Co., Ltd. Class H’s price range in the past 12 months?
WuXi AppTec Co., Ltd. Class H lowest stock price was HK$90.25 and its highest was HK$167.60 in the past 12 months.
What is WuXi AppTec Co., Ltd. Class H’s market cap?
WuXi AppTec Co., Ltd. Class H’s market cap is HK$405.95B.
When is WuXi AppTec Co., Ltd. Class H’s upcoming earnings report date?
WuXi AppTec Co., Ltd. Class H’s upcoming earnings report date is Aug 03, 2026 which is in 14 days.
How were WuXi AppTec Co., Ltd. Class H’s earnings last quarter?
WuXi AppTec Co., Ltd. Class H released its earnings results on Apr 27, 2026. The company reported HK$1.811 earnings per share for the quarter, beating the consensus estimate of HK$1.388 by HK$0.423.
Is WuXi AppTec Co., Ltd. Class H overvalued?
According to Wall Street analysts WuXi AppTec Co., Ltd. Class H’s price is currently Undervalued.
Does WuXi AppTec Co., Ltd. Class H pay dividends?
WuXi AppTec Co., Ltd. Class H pays a Annually dividend of HK$1.803 which represents an annual dividend yield of 1.43%. See more information on WuXi AppTec Co., Ltd. Class H dividends here
What is WuXi AppTec Co., Ltd. Class H’s EPS estimate?
WuXi AppTec Co., Ltd. Class H’s EPS estimate is 1.82.
How many shares outstanding does WuXi AppTec Co., Ltd. Class H have?
WuXi AppTec Co., Ltd. Class H has 510,476,900 shares outstanding.
What happened to WuXi AppTec Co., Ltd. Class H’s price movement after its last earnings report?
WuXi AppTec Co., Ltd. Class H reported an EPS of HK$1.811 in its last earnings report, beating expectations of HK$1.388. Following the earnings report the stock price went up 1.859%.
Which hedge fund is a major shareholder of WuXi AppTec Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2359
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
WuXi AppTec Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$168.20 (36.86% Upside)
HK$168.20 (36.86% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.09%
12-Months-Change
Fundamentals
Return on Equity
1.43%
Trailing 12-Months
Asset Growth
34.45%
Trailing 12-Months
Company Description
WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd. operates as an investment holding enterprise, delivering extensive research, development, and manufacturing services. These services primarily aid in the discovery, advancement, and production of small molecule pharmaceuticals, as well as sophisticated cell and gene therapies. The company maintains a global footprint, serving clients across the People's Republic of China, other Asian territories, the United States, Europe, and various international markets. Its operations are structured across six key segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. The firm's comprehensive offerings encompass contract research, development, and manufacturing organization (CRDMO) services, supporting new drug development from initial discovery phases all the way to commercial launch. This scope extends to diverse synthetic molecular types, including small molecules, oligonucleotides, peptides, and complex conjugates. Furthermore, WuXi AppTec provides biology services and solutions that facilitate projects from target identification to candidate selection and subsequent clinical progression. The company also offers integrated drug and medical device testing services, covering everything from preclinical assessments to clinical trials. An end-to-end solution is available to expedite the market entry of cell and gene therapies, alongside specialized drug discovery services for pharmaceutical and biotechnology clients, and full-spectrum clinical research support. WuXi AppTec Co., Ltd. was established in 2000 and its headquarters are located in Shanghai, People's Republic of China.
2359 Stock 12 Month Forecast
Average Price Target
HK$168.20
▲(36.86% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―